Court Wants FDA To Explain Decision To Use Unapproved Ebola Drug In Legal Case Surrounding ‘Right-To-Try’ Campaign

STAT: In tussle over ‘right to try,’ court presses FDA to shed light on Ebola drug decisions
“The Food and Drug Administration will have to explain to a court this week why it won’t shed more light on an internal decision to allow at least two Americans who contracted Ebola to take a drug that wasn’t yet approved. It’s the latest salvo in a legal case that could have broader implications for the ongoing campaign to pass a federal ‘right-to-try’ law, in which advocates are aiming to help dying patients get access to other drugs the FDA hasn’t yet approved…” (Mershon/Swetlitz, 3/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.